VNDA

5.27

0.29% 0.05

Dopo l'orario di chiusura: 5.26 -0.010 -0.19%

Vanda Pharmaceuticals Inc (VNDA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.22

Aprire:

$5.15

Volume 24 ore:

683.83K

Relative Volume:

0.72

Capitalizzazione di mercato:

$318.64M

Reddito:

$217.78M

Utile/perdita netta:

$-239.55M

Rapporto P/E:

-1.3015

EPS:

-4.0492

Flusso di cassa netto:

$-127.30M

1 W Prestazione:

+4.28%

1M Prestazione:

-3.77%

6M Prestazione:

-15.56%

1 anno Prestazione:

+20.07%

Intervallo 1D:

$5.13

$5.335

Intervallo di 1 settimana:

$4.849

$5.335

Portata 52W:

$4.27

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Nome

Vanda Pharmaceuticals Inc

Settore

Healthcare (1089)

Industria

Biotechnology (604)

Telefono

202-734-3400

Indirizzo

2200 PENNSYLVANIA AVE NW, WASHINGTON

Dipendente

533

Cinguettio

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VNDA Vanda Pharmaceuticals Inc	5.27	315.62M	217.78M	-239.55M	-127.30M	-4.0492
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-05	Iniziato	Truist	Buy
2025-11-05	Iniziato	B. Riley Securities	Buy
2024-10-31	Iniziato	H.C. Wainwright	Buy
2024-07-11	Iniziato	Cantor Fitzgerald	Overweight
2022-02-25	Downgrade	Jefferies	Buy → Hold
2021-05-12	Iniziato	BofA Securities	Buy
2021-01-14	Downgrade	Citigroup	Buy → Neutral
2020-10-29	Aggiornamento	Citigroup	Neutral → Buy
2020-06-09	Downgrade	Citigroup	Buy → Neutral
2020-03-16	Downgrade	Oppenheimer	Perform → Underperform
2020-03-12	Aggiornamento	Citigroup	Neutral → Buy
2019-11-07	Downgrade	Citigroup	Buy → Neutral
2019-08-01	Aggiornamento	Citigroup	Neutral → Buy
2019-07-25	Downgrade	Stifel	Buy → Hold
2018-12-11	Downgrade	Oppenheimer	Outperform → Perform
2018-12-04	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Reiterato	Jefferies	Buy
2018-11-08	Ripresa	Jefferies	Buy
2018-09-21	Ripresa	Oppenheimer	Outperform
2018-05-23	Iniziato	Citigroup	Buy
2018-01-19	Iniziato	Seaport Global Securities	Buy
2017-09-14	Reiterato	Piper Jaffray	Overweight
2017-06-27	Ripresa	Piper Jaffray	Overweight
2017-05-26	Iniziato	H.C. Wainwright	Buy
2017-04-12	Iniziato	Oppenheimer	Outperform
2016-11-09	Iniziato	Aegis Capital	Buy
2016-10-06	Ripresa	Jefferies	Buy

Mostra tutto

Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie

06:55 AM

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat

06:55 AM

Aug 16, 2026

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0

Aug 16, 2026

Aug 15, 2026

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits

Aug 15, 2026

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Aug 15, 2026

Aug 14, 2026

Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits

Aug 14, 2026

Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us

Aug 14, 2026

Aug 13, 2026

AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan

Aug 13, 2026

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026

Aug 12, 2026

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat

Aug 12, 2026

Aug 11, 2026

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Aug 11, 2026

Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits

Aug 11, 2026

Aug 10, 2026

VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus

Aug 10, 2026

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat

Aug 10, 2026

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada

Aug 10, 2026

VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 10, 2026